# Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

> **NCT02519842** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 75 (actual)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Fosaprepitant
- **DRUG:** Placebo for fosaprepitant
- **DRUG:** Ondansetron
- **DRUG:** Dexamethasone
- **DRUG:** 5-HT3 antagonist

## Key facts

- **NCT ID:** NCT02519842
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-14
- **Primary completion:** 2017-02-24
- **Final completion:** 2017-02-24
- **Target enrollment:** 75 (ACTUAL)
- **Why stopped:** Further data are no longer required to support an application for use in pediatric patients. The decision to terminate was not based on any new safety findings
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02519842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02519842, "Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02519842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*